Metozok

Metoprolol succinate, the active ingredient in Metozok, is a beta blocker presented as an oral dosage form for oral use. It is indicated for the management of hypertension, angina pectoris, chronic heart failure, and for post‑myocardial infarction prophylaxis in adult patients.

GNH USA supplies Metozok as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. Customers benefit from reliable delivery schedules and dedicated technical support.

Metozok (metoprolol succinate) is a beta‑blocker used in cardiovascular disease management, particularly conditions involving elevated blood pressure or cardiac workload. Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and cardiovascular events. Angina pectoris: decreases myocardial oxygen demand, relieving chest pain during exertion. Chronic heart failure: improves ventricular function and reduces hospitalizations by lowering heart rate and cardiac output. Post‑myocardial infarction prophylaxis: reduces the likelihood of recurrent infarction and mortality through long‑term heart rate control.

Metozok may be associated with a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headed sensation, especially on standing. - Gastrointestinal upset: nausea, abdominal discomfort or constipation. Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: significant drop in blood pressure causing faintness. - Bronchospasm: narrowing of airways, particularly in patients with asthma.

When prescribing Metozok, clinicians should consider several safety measures to minimize risks. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Heart rate assessment: ensure rate remains above safe threshold before dose changes. - Respiratory caution: use carefully in patients with asthma or chronic obstructive pulmonary disease. - Renal/hepatic function: adjust dose in moderate to severe impairment. - Discontinuation guidance: avoid abrupt cessation to prevent rebound hypertension or tachycardia. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Metozok can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Verapamil or diltiazem: combined use may cause profound bradycardia or heart block. - Clonidine withdrawal: abrupt discontinuation of clonidine while on Metozok can precipitate severe hypertension. - Amiodarone: increases plasma concentration of metoprolol, raising risk of adverse effects. Moderate Interactions (Monitor Closely): - Calcium channel blockers (non‑dihydropyridine): may enhance negative chronotropic effect. - ACE inhibitors or ARBs: additive blood pressure lowering, monitor for hypotension.